OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31

OPKO HEALTH, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026

$1.61+0.08 (+5.23%)

Close on Oct 19, 2026

Market cap: $1.22B
P/E (TTM): –
Dividend yield: –

OPKO HEALTH, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	607	713	863	1,004	1,775	1,435	902	990	966	1,117	492	91	97	47	28	28	4.42
Cost of Revenue	401	495	545	716	–	–	–	–	61	47	42	9.37	10	28	17	13	2.88
Gross Profit	206	219	318	288	–	–	–	–	905	1,070	450	82	86	19	11	15	1.54
Research & Development	124	105	90	74	77	75	118	126	126	114	99	84	54	20	11	5.95	11
Selling, General & Admin	223	304	301	373	469	356	343	358	415	407	197	58	55	28	19	18	10
Operating Expenses	–	–	1,021	1,230	1,756	1,378	1,176	1,161	1,242	1,214	590	237	176	84	51	26	24
Total Costs & Expenses	724	865	1,021	1,230	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-117	-152	-157	-226	19	58	-274	-171	-276	-97	-98	-146	-80	-37	-23	-11	-22
Interest Expense	0	47	14	12	19	–	–	–	–	–	–	–	–	–	1.01	1.22	1.76
Interest & Investment Income	15	8.43	3.98	1.98	0.03	–	–	–	–	–	–	–	–	0.19	0.29	0.02	0.02
Income from Equity Investments	-0.03	-0.02	-0.11	-0.38	-0.63	-0.48	-2.90	-14	-14	-7.65	-7.11	-3.59	-11	-2.06	-1.59	–	–
Other Non-Operating Income	-124	142	-27	-165	-33	-9.03	-31	-6.07	4.52	-0.27	-40	-25	-25	0.17	-1.04	-0.84	-1.92
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	0.79	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	92	22	13	0	–	–	–	–	–	–	–
Gain (Loss) on Investments	4.08	74	-0.53	-3.58	-0.63	-0.48	-2.90	-14	-14	-7.65	-7.11	-3.59	-11	-2.06	-1.59	-0.71	-0.35
Gain (Loss) on Sale of Assets	3.25	63	-1.32	0.46	34	11	-0.74	-0.05	8.66	-2.32	0	0	-0.06	0	0	–	–
Pretax Income	-241	-10	-184	-392	-14	49	-305	-177	-272	-97	-138	-171	-104	-37	-24	-12	-24
Income Tax Expense	-16	43	4.44	-63	15	18	7.06	-39	19	-56	-114	0.02	1.67	-9.63	-19	-0.02	-0.03
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	-117	-30	-6.46	-13	-24
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	0	0.11	5.18	-6.25	-5.72
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	-153	-305	-48	-31	-175	-117	-30	-1.28	-19	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	0	0	-1.40	-2.97	-2.94	-0.49	0	–	–
Net Income	-226	-53	-189	-328	-30	31	-315	-153	-305	-48	-30	-172	-114	-29	-1.28	-19	-30
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	0	0	0.42	2.24	2.38	2.62	4.72
Net Income to Common	–	–	–	–	–	–	–	-153	-305	-53	-30	-172	-115	-31	-3.66	-22	-35
EPS (Basic)(per share)	-0.30	-0.08	-0.25	-0.46	-0.05	0.05	-0.53	-0.27	-0.55	-0.09	-0.06	-0.41	-0.32	-0.11	-0.01	-0.08	-0.15
EPS (Diluted)(per share)	-0.30	-0.08	-0.25	-0.46	-0.05	0.05	-0.53	-0.27	-0.55	-0.10	-0.06	-0.41	-0.32	-0.11	-0.01	-0.08	–
Shares Outstanding (Basic, Weighted)(shares)	751	694	752	719	648	641	595	563	559	551	488	422	355	296	281	–	–
Shares Outstanding (Diluted, Weighted)(shares)	751	694	752	719	648	641	595	563	559	556	488	422	355	296	281	255	233
EBITDA	-26	-54	-52	-118	97	143	-180	-74	-174	0.03	-56	-131	-64	-27	-19	-8.93	-22

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 40.8%
Operating margin: -8.2%
Net margin: -12.4%
Return on equity, FY2025: -17.1%

Financial strength

Current ratio: 3.35
Debt to equity: 0.00
Debt to assets: 0.1%
Cash to current liabilities: 201.4%

Valuation

P/E ratio: –
Price to sales: 2.07
Price to book: 1.03
Dividend yield: –